A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children

Highlights ► Consistency of 3 lots of Hexaxim was demonstrated. ► Good immunogenicity following Hexaxim 2, 4, 6 month primary series, similar to control. ► High degree of antibody persistence at 15–18 months of age. ► Strong immune response following Hexaxim booster. ► No safety concerns for primary...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-10, Vol.30 (45), p.6492-6500
Main Authors: Aquino, Amalia Guadalupe Becerra, Brito, Maricruz Gutiérrez, Doniz, Carlos E. Aranza, Herrera, Juan Francisco Galán, Macias, Mercedes, Zambrano, Betzana, Plennevaux, Eric, Santos-Lima, Eduardo
Format: Article
Language:English
Subjects:
Age
Allergy and Immunology
Aluminum
Anorexia
Antibodies, Bacterial - blood
Antibodies, Viral - blood
Antigens
Booster vaccination
Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage
Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects
Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology
Haemophilus Vaccines - administration & dosage
Haemophilus Vaccines - adverse effects
Haemophilus Vaccines - immunology
Hepatitis
Hepatitis B Vaccines - administration & dosage
Hepatitis B Vaccines - adverse effects
Hepatitis B Vaccines - immunology
Hexavalent vaccine
Humans
Immune response
Immunization, Secondary
Immunogenicity
Infant
Licenses
Mexico
Poliovirus Vaccine, Inactivated - administration & dosage
Poliovirus Vaccine, Inactivated - adverse effects
Poliovirus Vaccine, Inactivated - immunology
Primary vaccination
Tetanus
Vaccines
Vaccines, Combined - administration & dosage
Vaccines, Combined - adverse effects
Vaccines, Combined - immunology
Whooping cough
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► Consistency of 3 lots of Hexaxim was demonstrated. ► Good immunogenicity following Hexaxim 2, 4, 6 month primary series, similar to control. ► High degree of antibody persistence at 15–18 months of age. ► Strong immune response following Hexaxim booster. ► No safety concerns for primary series or booster vaccinations.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.07.040